AccuMetab™ Canine CYP2B11 Enzyme, Catalytically Active

CAT#: ITS-0426-YL34
Product Type: Recombinant Phase I Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Canine CYP2B11 for reliable preclinical Phase I ADME profiling.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
Functioning as the major phenobarbital-inducible enzyme in dogs, CYP2B11 plays a dominant role in canine xenobiotic clearance. Profiling against this ortholog helps predict dog-specific Phase I metabolism, ensuring accurate interpretation of preclinical PK/PD and safety data.
Key Features
Dominant canine phenobarbital-inducible enzyme; Predicts first-pass clearance in dog models; Crucial for preclinical species bridging; Supplied in controlled, low-reductase formats
Applications
Drug Metabolism Studies, Preclinical Species Comparison
Research Areas
ADME; Veterinary Pharmacology
Species
Beagle
Expression System
Recombinant enzymes prepared from E. coli and co-expressed with NADPH CYP-reductase.
Physical Form
Liquid
Size
1 nmol
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Our enzyme products are shipped at -80°C.
For Research Use Only | Not For Clinical Use
Online Inquiry